Design, isolation and evaluation of the binding efficiency of a DNA aptamer against interleukin 2 receptor alpha, in vitro.

Design, isolation and evaluation of the binding efficiency of a DNA aptamer against interleukin 2 receptor alpha, in vitro.

International immunopharmacology (2017-10-22)

Mahin Shahdordizadeh, Seyed Mohammad Taghdisi, Mojtaba Sankian, Mohammad Ramezani, Khalil Abnous

RESUMEN

High levels of CD25, as part of the IL-2 receptor, are expressed on the surface of the activated T lymphocytes and regulatory T cells, indicating that the soluble CD25 (sCD25) could be a clinically valuable tool for treating several diseases. Moreover, progress has been achieved in targeting the IL-2 receptor to treat autoimmune diseases, organ transplantation and certain hematological malignancies. In the current study, generation of an ssDNA aptamer (Apt51) against CD25 is reported. Apt51 bound to CD25 with high affinity (K

MATERIALES

Referencia del producto

Marca

Descripción del producto

T0440

Sigma-Aldrich

Sistema de sustrato líquido 3,3′,5,5′-tetrametilbencidina (TMB) para ELISA, peroxidase substrate

S2438

Supelco

Polímero de estreptavidina−peroxidasa, ultrasensible